Novel targets overcome treatment resistance in triple-negative breast cancer
Patients with triple-negative breast cancer (TNBC), an aggressive subtype, currently have limited options and generally face a poor prognosis. Researchers led by Khandan Keyomarsi, Ph.D., Mi Li, Ph.D., and Amriti Lulla, Ph.D., discovered that increased levels of low molecular weight cyclin-E (LMW-E) and cyclin-dependent kinase (CDK1) phosphorylation are associated with poor outcomes following chemotherapy. High levels of LMW-E and CDK1 predicted the poorest treatment responses, suggesting they serve as potential biomarkers of chemotherapy resistance. The study showed that LMW-E upregulates...